Jump to content

OrbiMed

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Minkiboll (talk | contribs) at 10:26, 10 July 2024. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

OrbiMed Advisors LLC
FormerlyMehta & Isaly
Company typePrivate
IndustryInvestment management
Founded1998; 26 years ago (1998)
FounderSamuel Isaly
Michael Sheffery
Arvind Desai
HeadquartersCitigroup Center, New York City, New York, U.S.
ProductsPublic equity
Private equity
Venture capital
Private credit
AUMUS$21 billion (March 31, 2021)
Number of employees
100[1]
Websitewww.orbimed.com
Footnotes / references
[2]

OrbiMed (OrbiMed Advisors) is an American investment firm based in New York City, United States. It is focused on making public and private investments in the Healthcare and Biotechnology industries. OrbiMed is considered one of the world's largest dedicated healthcare investment firms.[3]

Background

In 1989, S.G Warburg pharmaceutical analysts Viren Mehta and Samuel Isaly founded Mehta & Isaly, a money-management and research firm. This was the predecessor firm to OrbiMed.[3][4][5][6][7] The firm made its first venture capital investment in 1993.[7]

In 1998, Mehta & Isaly split up into two entities, with Mehta forming Mehta Partners and Isaly forming OrbiMed Advisors.[3][5][8]

In 2007, OrbiMed expanded into Asia, opening offices in Shanghai and Mumbai. In 2010, the firm expanded into the Middle East, opening an office in Herzliya, Israel.[9]

In December 2017, Isaly stepped down from his role as managing partner of OrbiMed due to allegations of sexual harassment raised by former female employees.[4][7][10][11]

Notable investments

References

  1. ^ "Sponsors for the 13th ELSF Forum". SachsForum.
  2. ^ "Form ADV as of 3/30/2021" (PDF). SEC.gov. Archived from the original (PDF) on May 22, 2021.
  3. ^ a b c "Orbimed drug portfolio balances prognosis with prevention". Institutional Investor. September 22, 2009. Retrieved July 15, 2023.
  4. ^ a b "ObriMed Advisors founder to step down, be replaced by management committee". Pensions & Investments. December 8, 2017. Retrieved May 22, 2021.
  5. ^ a b "Mehta & Isaly Investment Firm Splits". The New York Times. January 6, 1998. ISSN 0362-4331. Retrieved May 22, 2021.
  6. ^ Kreutzer, Laura. "OrbiMed Seeks $4.75 Billion for Fresh Slate of Healthcare-Focused Funds". WSJ. Retrieved July 15, 2023.
  7. ^ a b c McElhaney, Alicia (January 3, 2018). "Their Hedge Fund's Founder Was Accused of Sexual Harassment. Here's What They Did Next". Institutional Investor. Retrieved July 15, 2023.
  8. ^ "OrbiMed Advisors". FierceBiotech. October 8, 2014. Retrieved May 22, 2021.
  9. ^ "ORBIMED ADVISORS LLC Profile and Investing Strategy - GuruFocus.com". www.gurufocus.com. Retrieved May 22, 2021.
  10. ^ "Isaly steps down from hedge fund giant OrbiMed after harassment claims". STAT. December 8, 2017. Retrieved May 22, 2021.
  11. ^ Norton, Leslie P. "OrbiMed's Sam Isaly Steps Down Amid Accusations of Sexual Misconduct". www.barrons.com. Retrieved May 22, 2021.
  12. ^ "AbCellera Closes $105 Million Series B Financing to Further Advance World-Leading Antibody Drug Discovery Platform". www.abcellera.com. Retrieved May 22, 2021.
  13. ^ Baum, Stephanie (November 1, 2013). "OrbiMed closes its largest VC fund, predicts rebound in healthcare investing in 2014". MedCity News. Retrieved May 22, 2021.
  14. ^ "Ambit Biosciences Completes $30 Million Series D-2 Financing". www.businesswire.com. June 10, 2011. Retrieved May 22, 2021.
  15. ^ "BRIEF-Orbimed Advisors acquired 480,000 common shares of Cynapsus Therapeutics". Reuters. July 7, 2016. Retrieved May 22, 2021.
  16. ^ "DFine raises $36.2M to repair spine fractures". VentureBeat. July 16, 2010. Retrieved May 22, 2021.
  17. ^ Says, Anon (January 3, 2008). "Xconomy: Obesity Startup Gelesis Gobbles Up $16M in Financing". Xconomy. Archived from the original on June 30, 2008. Retrieved May 22, 2021.
  18. ^ "Intercept Pharmaceuticals Closes $30 Million Series C Financing". www.prnewswire.com (Press release). Retrieved May 22, 2021.
  19. ^ "Natera Completes $54.6 Million Financing to Support Expansion, Continued Global Rollout of Non-Invasive Prenatal Test Panorama™ | Natera, Inc". investor.natera.com. Retrieved May 22, 2021.
  20. ^ Hay, Timothy (August 28, 2012). "OmniGuide Raises $35M in Debt From OrbiMed Advisors". Wall Street Journal. ISSN 0099-9660. Retrieved May 22, 2021.
  21. ^ "TigerText Closes on $50 Million in Financing to Accelerate Growth; Launches TigerText Anywhere Initiative". TigerConnect. Retrieved May 22, 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=OrbiMed&oldid=1233682795"